Core Viewpoint - PROCEPT BioRobotics Corporation reported a strong financial performance for Q2 2025, with a 48% year-over-year revenue growth, driven by increased demand for its Aquablation therapy and expansion in both U.S. and international markets [3][4]. Financial Performance - Total revenue for Q2 2025 was $79.2 million, a 48% increase compared to Q2 2024 [4][9]. - U.S. revenue reached $69.6 million, reflecting a 46% growth year-over-year, primarily from system sales and increased handpiece revenue [4][9]. - International revenue was $9.6 million, marking a 69% increase compared to the prior year [4][9]. - U.S. handpiece and consumable revenue was $43.1 million, up 58% year-over-year [4][9]. - Gross margin improved to 65% in Q2 2025 from 59% in the prior year, attributed to operational efficiencies and higher selling prices [5]. Operating Expenses and Losses - Operating expenses for Q2 2025 were $73.9 million, up from $58.3 million in Q2 2024, driven by expansion of the commercial organization and increased R&D expenses [6]. - The net loss for Q2 2025 was $19.6 million, an improvement from a loss of $25.6 million in the same period last year [7][9]. - Adjusted EBITDA loss was $8.0 million for Q2 2025, compared to a loss of $17.9 million in Q2 2024 [7][9]. Future Guidance - The company projects full-year 2025 revenue to be approximately $325.5 million, representing a 45% growth over the previous year [8][9]. - Full-year 2025 gross margin is expected to be around 64.5% [15]. - The company anticipates total operating expenses for 2025 to be approximately $302.0 million [15]. Leadership Changes - Larry Wood has been appointed as the new CEO, effective September 2, 2025, bringing 40 years of experience in the medical technology industry [9]. Product and Market Focus - The company is focused on expanding the utilization of Aquablation therapy in the U.S. and enhancing its presence in international markets [3]. - PROCEPT BioRobotics aims to revolutionize BPH treatment globally through its robotic solutions, which are designed to deliver effective outcomes for patients [11].

Core Viewpoint - PROCEPT BioRobotics Corporation is set to report its financial results for Q2 2025 on August 6, 2025, with a conference call scheduled for the same day [1]. Company Overview - PROCEPT BioRobotics focuses on advancing patient care in urology through innovative surgical robotics solutions [1]. - The company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3]. - Aquablation therapy is designed to provide effective and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), regardless of prostate size or surgeon experience [3]. - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for the company's solutions [3]. - The company has established a robust clinical foundation with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3].

Group 1 - The company, PROCEPT BioRobotics, is focused on advancing patient care in urology through transformative robotic solutions [3] - The company will present at four investor conferences in May and June 2025, including the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference [1][2] - PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] Group 2 - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [3] - The company has developed a significant body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [3] - The company aims to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions [3]